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Sumlllal'y 
To gain more insight into the role of HIV-l-specific cytotoxic T  lymphocytes (CTL) in the 
pathogenesis of AIDS, we investigated temporal relations between HIV-1 Gag-specific precursor 
CTL (CTLp), HIV-1 viral load, CD4 + T cell counts, and T cell function. Six HIV-l-infected 
subjects, who were asymptomatic for more than 8 yr with CD4 + counts >500 ceUs/mm  3, were 
compared with six subjects who progressed to AIDS within 5 yr after HIV-1 seroconversion. 
In the long-term asymptomatics, persistent HIV-1 Gag-specific CTL responses and very low 
numbers of HIV-l-infected CD4 + T cells coincided with normal and stable CD4 + counts and 
preserved CD3 mAb-induced T cell reactivity for more than 8 yr. In five out of six rapid progressors 
Gag-specific CTLp were also detected. However,  early in infection the number of circulating 
HIV-l-infected  CD4 +  T  cells increased  despite  strong  and  mounting Gag-specific  CTL 
responses. During subsequent clinical progression to AIDS, loss of Gag-specific CTLp coincided 
with precipitating CD4 +  counts and  severe deterioration of T  cell function. The possible 
relationships of HIV-1 Gag-specific CTLp to disease progression are discussed. 
D 
uring progressive  HIV-1 infection immune responses 
deteriorate with subsequent development of AIDS. Al- 
though several correlates for progression to AIDS have been 
identified, the exact mechanisms underlying immune dysfunc- 
tion remain to be elucidated (1, 2).  The clinical course of 
HIV-1 infection is determined by complex interactions be- 
tween viral parameters, host properties, and cofactors. Virus- 
specific CTL that kill virus-infected cells are thought to be 
a major host defense against viral infections (3). Therefore, 
HIV-l-specific CTL may be important for controlling viral 
spread during acute HIV-1 infection (4) and for maintaining 
viral load at low levels during the asymptomatic phase (5). 
Observations from cross-sectional studies have shown absent 
or severely depressed HIV-l-specific CTL responses during 
advanced stages of HIV-1 infection (6-8). These studies how- 
ever, have not resolved whether rapid progressors  are non- 
responders to HIV-1  or whether HIV-l-specific CTL re- 
sponses  are  elicited  which  subsequently diminish during 
progression to AIDS. In contrast, strong HIV-l-specific CTL 
responses have been proposed to cause immunosuppression 
in HIV-1 infection rather than being beneficial (9). 
To gain more insight in the role of HIV-l-specific CTL 
in the pathogenesis of AIDS, we analyzed long-term asymp- 
tomatics (LTA)  1 and rapid progressors  for precursor CTL 
(CTLp) specific for Gag, the protein of HIV-1 which is most 
predominantly recognized by CTL  during asymptomatic 
HIV-1 infection (10-16).  Longitudinal studies were under- 
taken to investigate temporal relations between Gag-specific 
CTLp, HIV-1 viral load, immune status, and clinical course 
of HIV-1 infection. 
1 Abbreviations  used in this  pa~r. B-LCL, B-lymphoblastoid  cell line; CDC, 
Centers for Disease Control;  CI, confidence interval; CTLp, precursor 
CTL; LTA, long-term asymptomatics; (N)SI, (non-)syncytium inducing; 
rVV, recombinant vaccinia virus; TCID,  tissue culture infectious dose. 
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Study Population.  The Amsterdam Cohort Studies on AIDS were 
initiated in October 1984 (17). Data about cohort participants were 
collected in three monthly visits that consisted  of a standardized 
medical history and collection of  blood samples for HIV-1 serology 
and cellular  immunology. Date of entry for participants already 
HIV-1 seropositive at enrollment, or documented HIV-1 serocon- 
version,  taken as the midpoint between the last seronegative  and 
first  seropositive  visit,  were used as reference points for clinical 
follow-up.  Previously it was  shown that participants who were 
HIV-1 seropositive at entry in the study, seroconverted within 1.5 yr 
before enrollment (18). By December 1991 there were 106 co- 
hort-participants with documented HIV-1 seroconversion. By De- 
cember 1992, 34 of these seroconvertors were diagnosed with AIDS 
(19, 20) according to 1987 Centers for Disease Control (CDC) 
classifications  (21). For this  study,  six cohort participants were 
studied, who progressed to AIDS within 5 yr after HIV-1 serocon- 
version: P159, P186, P187, P224,  P450, and P748.  From 273 co- 
hort-participants who either entered the study as HIV-1 seroposi- 
tive or seroconverted before  January 1986, 61 participants remained 
asymptomatic (CDC II/III) for more than 7 yr (22). For this study, 
six LTA were selected, who had at least 8 yr of asymptomatic follow- 
up and CD4 § T cell counts >500 cells/mm3: L008, L067, L090, 
L617, L709, and L206. Subject L206 is a patient who is monitored 
at The Academic Medical  Centre in Amsterdam. 
Immunological  Markers.  T lymphocyte immunophenotyping for 
CD4 and CD8 membrane markers was carried out at three monthly 
intervals by flow cytofluorometry. PBMC were stained with CD4 
mAb (Leu-3a-PE; Becton Dickinson, Mountain View, CA) or CD8 
mAb (Leu-2a-PE;  Becton Dickinson) according to the manufac- 
turer's protocols. Polyclonal T cell functions were measured in real 
time after May 1987 as previously described (23), by measuring 
the CD3-mAb (CLB-T3/4E; CLB, Amsterdam, The Netherlands) 
induced proliferative  capacity of PBMC in whole-blood cultures. 
T  cell reactivity is expressed  as counts per minute. 
Recombinant Vaccinia Viruses  (rVV).  rVV used in these studies 
were constructed from the Copenhagen strain  of Vaccinia virus, 
and include rVV TG.1144 expressing Gag of HIV-1L,~ (24, 25) and 
control-rVV  186-poly  containing no insert;  kindly provided by 
Dr. Y. P,  ivi~re (Institut Pasteur, Paris, France) and Dr. M.P. Kieny 
(Transg~ne S.A.,  Strasbourg,  France). 
Induction of HIV-l-specific  CTL  Responses.  HIV-l-specific 
CTLp were expanded in vitro by Ag-specific stimulation as previ- 
ously described  (15). Frequencies  of Gag-specific CTLp were de- 
termined using standard methods of limiting dilution analysis (26). 
Briefly, PBMC isolated and cryopreserved at different time points 
during the study were thawed and resuspended  in IMDM sup- 
plemented with antibiotics and 10% pooled human serum. Eight 
serial dilutions of PBMC ranging from 20,000 to 745 cells/well 
were seeded in 24-fold in 96-well round-bottom microtiter plates. 
Stimulator  cells  were  autologous  EBV-transformed  B- 
lymphoblastoid cell lines (B-LCL) infected with rVV-TG.1144 and 
subsequently  inactivated with paraformaldehyde. To each well, 104 
fixed stimulator cells and 104 autologous PBMC (30 Gy irradiated) 
were added, and microcultures were maintained for 15 d at 37~ 
and 5% CO2. At day 2 and 9 cultures were fed with medium con- 
taining rlL-2 (10 U/ml; Cetus Corp., Emeryville, CA), and at day 
7 they were restimulated with 104 fixed stimulator cells and rlL-2 
(10 U/ml).  On day 15, wells were split  and effector cells tested 
for cytotoxicity. 
Cytotoxicity Assays.  Standard slChromium-release assays were 
performed as previously described (15). Briefly, autologous B-LCL 
were infected with 5 MOI rVV-TG.1144 or rVV 186-poly and la- 
beled with Na251CrO4 (Amersham Intl., Amersham, Bucks, UK) 
for 16 h. After three additional washings,  4  x 103 target cells were 
added to each well. After 4 h, supernatants were harvested and 
radioactivity was counted on 3-counter (Cobra II; Packard Instr. 
Co.,  Inc.,  Meriden,  CT).  Spontaneous SlCr-release was  always 
<15% of maximum release. Specific lysis was calculated with the 
formula: 100x  ([experimental release -  spontaneous release]/[max- 
imum release -  spontaneous release]). Wells were considered posi- 
tive when the SlCr-release exceeded 10% specific lysis. Statistical 
analysis was performed using methods as previously has been de- 
scribed by Strijbosch et al. (27). CTLp frequencies are expressed as 
number of CTLp/10  ~ PBMC. Gag-CTLp frequencies were com- 
puted as differences between CTLp frequencies determined on Gag- 
expressing versus control targets. The average CTLp-frequency on 
control targets was <25/106 PBMC. 
Virological  Markers.  Viral load in peripheral blood samples was 
determined using clonal virus isolation procedures as previously 
described  (28).  Briefly, 12,500-25,000 PBMC of HIV-l-infected 
patients were cocultivated with 103 2-d PHA-stimulated PBMC 
from HIV-1 seronegative blood donors. HIV-1 replication was moni- 
tored by screening culture supernatants for p24 production using 
a p24 capture ELISA. Statistical analysis of positive wells was per- 
formed using methods as previously has been described  by Strij- 
bosch et al. (27). Viral burden was expressed as tissue culture infec- 
tious dose (TCID)/106 CD4 + T cells, representing the number of 
cells productively infected with HIV-1 in the peripheral blood. Bi- 
ological phenotype of HIV-1 viruses was determined as previously 
described (29). Briefly, 106 PBMC of HIV-l-infected patients were 
cocultivated with MT2 cells, and cultures were monitored micro- 
scopically several times per week to check for syncytium formation 
to determine the viral phenotype. 
Results 
Natural History of HIV-1  Infection in Long-term Asympto- 
matics and Rapid Progressors.  Six LTA who were selected for 
this study remained asymptomatic for >8.0 yr with CD4 + 
counts  >500/mm 3.  Total  follow-up  period  until  October 
1994 was 9.6  _+  0.4 yr. In addition, six cohort-participants 
who progressed to AIDS within 5 yr after HIV-1 serocon- 
version were also longitudinally studied. Mean time between 
HIV-1  seroconversion and AIDS diagnosis was  3.8  _+  1.2 
yr. Clinical and laboratory findings of all studied subjects are 
presented in Table 1. Except for H86, all progressors suffered 
from severe to mild influenza-like disease in the 3 mo preceding 
HIV-1 seroconversion indicative for symptomatic acute HIV-1 
infection (19), whereas none of the LTA reported history of 
primary HIV-1 infection in the months preceding serocon- 
version or enrollment  in the cohort study. 
CD4 § T  cell numbers in LTA were in the range of values 
found in healthy uninfected controls (90% confidence interval 
(CI): 560-1,550/mm3).  CD4 + T  cell counts of L090, L617, 
and L709 remained stable, whereas in subjects L008, L067, 
and L206, CD4 + counts tended to decline towards the end 
of the study. CD8 + T  cell numbers of L617 and L206 were 
increased,  whereas  in  other  LTA CD8 +  T  cell counts  re- 
mained within  normal  range  (90%  CI:  310-1,000/mm3). 
CD4 +/CD8 + ratios were clearly reversed in L617; while in 
subjects L008, L067, and L206, ratios inverted after •5-6  yr 
of follow up (Fig. 1 A).  Upon HIV-1 seroconversion CD4 + 
counts rapidly declined in five out of six progressors with 
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Seroconversion  Virus  AIDS 
Subjects  HLA Class I*  status*  Ages  phenotypell  diagnosis  I  Follow-up** 
LTA 
L008  A2,26;B27,44;Cw1,6  II  38  SI (95)  NA  >119 
L067  A26,28;B7,57;Cw7  II  35  NSI  NA  >119 
L090  A1,2;B41,57;Cw6  I  41  NSI  NA  116 
L617  A2,11;B35,62;Cw3  II  28  NSI  NA  >115 
L709  A1,69;B14,57;Cw6  I  29  NSI  NA  108 
L206  A3,25;B18,51  II  31  NSI  NA  >111 
Progressors 
P159  A1;B8;Cw7  I  46  SI (18)  CAO,  PCP  32 
P186  A3,24;B60,Cw3,4  I  30  NSI  PCP  42 
P187  A1;B8;Cw7  I  34  SI (1)  HSV, TXP  28 
P224  A3;B44,51;Cw4,7  I  28  SI (45)  PCP  60 
P450  A24,28;B39,44  I  29  SI (52)  KS  65 
P748  A1;B8;Cw7  I  29  SI (31)  CD4 <200  47 
* HLA class-I typings were performed at Department Transplantation Immunology, CLB, Amsterdam, using standard serological typing methods. 
* Known date of HIV-1 seroconversion (I) or seropositive upon entry in the cohort study (II). 
S Age O  r) at HIV-1 seroconversion or first seropositive visit. 
II Biological virus phenotype: NSI vs. SI; number of months after seroconversion  or seropositive  entry at which NS1 to SI switch occurred indicated 
in parentheses. 
AIDS diagnosis according to CDC classifications (21): PCP, pneumocystis carinii pneumonia; HSV, Herpes Simplex virus infection; TXP, Toxoplas- 
moils; CAO, Candida albicans oesophagitis; KS, Kaposi's sarcoma or CD4 + T cell numbers <200/mm3; NA, not applicable for LTA. 
** Time (too) between HIV-1 seroconversion or seropositive entry and AIDS diagnosis for progressors or October 1994 for LTA. 
>140 cdls/mm 3 per year. In subject P224 CD4 § counts ini- 
tially remained quite stable, but dropped precipitously after 
45 mo of infection. In general,  CD4 +/CD8 + ratios were in- 
verted after seroconversion, which in patients P159 and P186 
was also due to elevated CD8 + T cell numbers (>l,000/mm 3) 
(Fig.  1 D). T cell function of LTA, measured by CD3 mAb- 
induced  proliferation,  was stable and within  the range  of 
normal values (90% Ch  1,100-10,100 cpm), whereas T cell 
function  in  all  progressors  gradually diminished  to below 
normal values (Fig. 2). We have shown this to be predictive 
for progression  to AIDS (23). 
Subject P748 remained asymptomatic during foUow-up but 
CD4 §  counts  dropped  <200  cells/ram 3 within  4  yr after 
seroconversion. Currently P748 is being treated with AZT 
and pneumocystis  carinii pneumonia (PCP) prophylaxis. Sub- 
ject P187 became infected with HIV-1 after unprotected sexual 
intercourse with an AIDS patient. Six months after serocon- 
version he was lost for the cohort study, but kept monitored 
by a local general practitioner who also conducted AZT anti- 
retroviral therapy and PCP prophylaxis. Subject P450 suffered 
from multiple allergic complaints during all stages of HIV-1 
infection.  General  skin  rash,  eczema,  erythema,  and  der- 
matomycosis were observed, as well as allergic reactions to 
rubber and allergic skin rash after treatment  with erythro- 
mycin, cotrimoxazol, and ciprofloxacin.  Except for L008 who 
started AZT treatment  at  109 mo after entry,  none of the 
LTA was subjected to anti-retroviral  therapy. 
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Longitudinal Analysis of HIV-1 Gag-specific CTL Responses. 
During the entire follow-up period of the study Gag-specific 
CTL responses could be detected in all LTA. The observed 
CTLp  frequencies  were  between  1/300-1/21,000;  in  the 
same range as previously has been reported by other inves- 
tigators (8, 10, 13). In subjects L067 and L206, strong (av- 
erage  of >300  CTLp/106  PBMC)  persistent  Gag-specific 
CTL responses were detectable although they tended to de- 
cline at later time points (Fig.  1 B). Subjects L008,  L617, 
and L090 had stable intermediate (average of 100-300 CTLp/ 
106 PBMC) Gag-specific CTL activity during follow-up. Fi- 
nally,  subject  L709  showed  persistent  but  lower  (average 
20--100 CTLp/106 PBMC) Gag-specific  CTL responses (Fig. 
1 B). In addition, CTL responses from subjects L206, L008, 
and L617 were analyzed in greater detail, using series of over- 
lapping peptides spanning the entire Gag sequence of HIV- 
1L^,. Multiple CTL epitopes were identified mainly localized 
in Gag-p24 (15). In addition,  after 7 yr of follow-up, CTLp 
frequencies for Nef and Env in subject L206 were only 53 
and 32/106 PBMC,  respectively;  7-10-fold lower than  the 
Gag-specific CTLp frequency. In blood sampled from subject 
L090 5.7 and 7.7 yr after seroconversion no Env-specific CTL 
directed against  the HIV-1L^, sequence could be detected. 
All tested progressors, except for patient P450, showed dis- 
tinct Gag-specific CTL responses after seroconversion albeit 
with different kinetics (Fig.  1 E).  Participants  P159, H86, 
and P748 initially showed strong though transient  Gag-specific a)  T-cell counts 
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Figure 2,  Longitudinal analysis of CD3-mAb induced T  cell reactivity. Follow up on x-axis indicates time (mo) after HIV-1 seroconversion or 
HIV-l-seropositive  entry in the study. In vitro T cell function (@) of LTA (A) and progressors (B) is measured by whole blood proliferation assays 
using CD3 mAb, and is expressed as cpm.  90% CI of normal values are indicated by <>. 
CTL responses during the first 2 yr after seroconversion,  with 
frequencies up to 700-1,400/106  PBMC. Gag-specific CTL 
responses in patient P224 gradually subsided over time.  In 
patient P450 repeatedly no Gag-specific CTL responses could 
be detected in blood samples from 10 different time points 
(Fig.  1 E). 
Virological Characteristics during the Clinical Course of HIV-1 
Infection.  In  general,  the  number  of circulating  HIV-1- 
infected CD4 + T cells was low in LTA. From blood samples 
of subjects L090 and L709 only 2, respectively, 3 virus clones 
were isolated at 65, respectively, 24 and 78 too. From sub- 
jects L067  and L206,  virus could only be isolated at later 
time points. On average, viral load was <5 TCID/106 CD4 + 
T cells. From L617, virus could be isolated at all time points 
tested;  the  frequency  of infected cells  was  low,  although 
it tended  to  increase  towards  the  end  of the  study  (<25 
TCID/106  CD4 +  T  cells).  In  subject  L008,  there  was  a 
sudden increase of viral load up to 100 TCID/106 CD4 § T 
cells after 91 mo of follow-up, coinciding with a change in 
viral phenotype (Fig. 1 C and Table 1). In all patients studied, 
viral load increased during progression to AIDS,  with the 
number of infected cells up to 81-415 TCID/106 CD4 + T 
cells.  Except for patient  P186,  all progressors  studied here 
developed AIDS with SI HIV-1 variants.  Viral load in pa- 
tient P450 showed a biphasic course, and the emergence of 
SI-variants coincided with a high number of HIV-l-infected 
CD4 + T  cells  4 mo before AIDS diagnosis.  Increased de- 
cline of CD4 + T  cells and accelerated progression to AIDS 
is strongly associated with emergence of SI variants (30), which 
was most obvious in patient  P224 (Fig.  1 F). 
Discussion 
We evaluated HIV-1 Gag-specific CTLp, HIV-1 viral load 
and general immune  status in relation to clinical  course of 
HIV-1 infection, to gain more insight in temporal relations 
between HIV-1 replication  and host immune  responses. 
Persistent  Gag-specific CTL responses and low numbers 
Figure  1.  Natural history of HIV-1 infection in LTA and rapid progressors. Follow up on x-axis indicates time (mo) after HIV-1 seroconversion 
or HIV-l-seropositive  entry in the study. (A and D) Longitudinal analysis of CD4 (@) and CD8 (~7) T lymphocyte subsets. Reference values (90% 
CI) for CD4* and CD8 + subsets were determined in a group of healthy HIV-l-seronegative  volunteers (n  =  430), and ranged from 0.56-1.55  and 
0.31-1.00-109  cells/L, respectively. Arrows (A) indicate time points when NSI to Sl-phenotype switch occurred or date of AIDS diagnosis. (B and 
E) Longitudinal analysis of HIV-1 Gag-specific CTL responses in cryopreserved blood samples. Ag-specific CTL effectors were tested in split-well 
slChromium-release assay on autologous B-LCL infected with rVV TG.1144 expressing gag or control targets infected with rVV 186 poly, containing 
no insert. Gag-CTLp frequencies (V) were computed as differences  between CTLp frequencies determined on gag versus control targets and normalized 
to the number of CTLp per 10~ PBMC.  Error bars indicate standard error of calculated frequencies. (C and k-) Longitudinal analysis of HIV-1 viral 
load in peripheral blood samples. HIV-1 viral load was determined with clonal virus isolation procedures. The number of cells productively infected 
with HIV-1 is expressed as TCID/106  CD4 + T  cells (m). 
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in LTA, together with stable and normal CD4 § counts and 
preserved T cell functions for more than 8 yr. This may indi- 
cate that HIV-1 Gag-specific CTL contribute to maintenance 
of the asymptomatic state by effectively controlling HIV-1 
replication. However, in four out of six progressors, a rise of 
Gag-specific  CTLp frequencies early in infection was paral- 
leled by increasing numbers of HIV-l-infected CD4 + T cells. 
During subsequent progression, Gag-CTLp frequencies de- 
creased severely in three out of four progressors.  Subject P748 
with CD4 § counts dropping below 200 cells/ram  3, impaired 
T cell function, SI viruses,  and increasing viral load, all pre- 
dictive for rapid progression to AIDS (2, 31), remained asymp- 
tomatic during follow-up. In this patient, Gag-specific CTLp 
remained relatively stable during the study period, which may 
be related to anti-retroviral treatment (32), In subject P224, 
Gag-specific CTL responses gradually decreased during pro- 
gression to AIDS. At the time when CTLp frequencies were 
very low, an increase in viral load, change in biological viral 
phenotype and subsequent progressive depletion of CD4 + 
T cells was observed (1, 2). In progressor P450, no Gag-specific 
CTLp were detected at all. However, it could be that CTL 
recognizing strain-specific  sequences of autologous HIV-1 
variants are present that are not detected using prototype 
HIV-1  sequences.  Furthermore, the presence of efficacious 
CTL responses directed against other antigens of HIV-1 can 
also not be excluded at the present time. 
This longitudinal analysis revealed that five out of six rapid 
progressors were able to mount substantial Gag-specific CTL 
responses early in infection, with magnitudes comparable to 
those observed in LTA. In contrast to observations in LTA 
however, Gag-specific CTL responses were only transient and 
disappeared during progression to AIDS, apparently failing 
to contain viral replication and spread. Increase of viral load 
in the face of mounting Gag-specific  CTL responses might 
be due to expanding HIV-1 variants which have escaped from 
CTL recognition (33), but a clear demonstration that these 
escape variants have selective advantage in vivo is still lacking 
(34,  35).  Another explanation may be that, although CTL 
can be detected in vitro,  they may not be able  to execute 
effector functions in vivo.  For example, IL-10,  an immuno- 
suppressive  cytokine, which has been reported to induce a 
state of tolerance by downregulating allogeneic CTL responses 
in human long-term chimeric patients that received HLA-mis- 
matched bone marrow transplants (36), may have frustrated 
in vivo CTL function in rapid progressors (37). In addition, 
as has been shown for mice infected with lymphocytic cho- 
riomeningitis virus, persistent viral infections may exhaust 
virus-specific  effector CTL resulting in loss of immune sur- 
veillance  (38). 
Zinkernagel and Hengartner (9), have suggested that strong 
CTL responses in fact could be instrumental in deteriorating 
the  immune  system by  depleting  HIV-l-infected  CD4 + 
T cells and APC.  In LTA however, vigourous Gag-specific 
responses  were not detrimental per se,  since little loss  of 
CD4 § T cells and well preserved T  cell function were ob- 
served for more than 8 yr. In patients P224  and 450,  pre- 
cipitous loss of CD4 + T cells and T cell function were ob- 
served, only when changes in viral phenotype and viral load 
occurred, pointing to a role for HIV-1 next to cellular im- 
munity in determining kinetics of clinical progression (28, 30). 
In conclusion, our results show that long-term asymptom- 
atic HIV-1  infection is  characterized by sustained HIV-1 
Gag-specific CTL responses and low numbers of circulating 
HIV-l-infected CD4 + T cells. Rapid progressors,  however, 
were not protected from disease progression despite high 
Gag-specific  CTLp  frequencies early in  HIV-1  infection. 
Besides quantitative aspects of Gag-specific CTL as analyzed 
here, repertoire differences and phenotypical and functional 
differences in CTL may contribute to control of HIV-1 in- 
fection (39). 
Alternatively, based on these data, one could argue that 
HIV-l-specific CTL responses do not play a critical role in 
determining the rate of progression to AIDS. Sustained HIV- 
1-specific CTL activity may merely be a reflection of preserved 
cellular immunity as observed during long-term asymptom- 
atic HIV-1 infection (22). Loss of HIV-l-specific CTL may 
be a reflection of progressive immunodeficiency induced by 
HIV-1 infection (1, 2). Our observations in the progressors 
suggest that  HIV-l-induced perturbation  of the immune 
system, rather than loss  of HIV-l-specific CTL,  could be 
the critical event. Clinical outcome of HIV-1 infection may 
be determined by host genetics (20), virulence of H IV-1 vari- 
ants (40,  41),  as well as by virus-host interactions already 
at the time of primary HIV-1 infection (42). Thus, our results 
warrant more detailed studies into  underlying pathogenic 
mechanisms causing immune dysfunction to better under- 
stand differences between long-term asymptomatic HIV-1 
infection and rapid progression to AIDS. 
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